Published in BMC Med Genomics on July 22, 2011
TGF-β signaling in myeloid cells is required for tumor metastasis. Cancer Discov (2013) 1.76
Understanding disease mechanisms with models of signaling pathway activities. BMC Syst Biol (2014) 1.00
Gene expression-based classifiers identify Staphylococcus aureus infection in mice and humans. PLoS One (2013) 0.99
Host gene expression profiling and in vivo cytokine studies to characterize the role of linezolid and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA) murine sepsis model. PLoS One (2013) 0.86
Functional networking of human divergently paired genes (DPGs). PLoS One (2013) 0.83
GRACOMICS: software for graphical comparison of multiple results with omics data. BMC Genomics (2015) 0.80
Network-based Prediction of Cancer under Genetic Storm. Cancer Inform (2014) 0.79
Peripheral blood cells inform on the presence of breast cancer: a population-based case-control study. Int J Cancer (2014) 0.79
Comprehensive tissue-specific gene set enrichment analysis and transcription factor analysis of breast cancer by integrating 14 gene expression datasets. Oncotarget (2016) 0.75
Evaluation of MCT1, MCT4 and CD147 Genes in Peripheral Blood Cells of Breast Cancer Patients and Their Potential Use as Diagnostic and Prognostic Markers. Int J Mol Sci (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol (2006) 20.28
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med (2003) 11.23
Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. Radiology (2002) 7.48
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nat Biotechnol (2010) 7.08
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics (2007) 6.63
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA (2004) 5.85
Screening for breast cancer. JAMA (2005) 4.56
Gene expression signatures diagnose influenza and other symptomatic respiratory viral infections in humans. Cell Host Microbe (2009) 4.55
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development. Cell (1986) 3.70
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Breast tumor characteristics as predictors of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst (1999) 2.49
Likelihood ratios for modern screening mammography. Risk of breast cancer based on age and mammographic interpretation. JAMA (1996) 2.44
Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res (2005) 2.00
Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res (2009) 1.86
Peripheral blood gene expression profiling in rheumatoid arthritis. Genes Immun (2005) 1.66
Gene expression profiling of peripheral blood cells for early detection of breast cancer. Breast Cancer Res (2010) 1.64
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma. Cancer Res (2003) 1.59
Gene expression in peripheral blood differs after cardioembolic compared with large-vessel atherosclerotic stroke: biomarkers for the etiology of ischemic stroke. J Cereb Blood Flow Metab (2008) 1.50
Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res (2006) 1.44
Breast cancer tumor growth estimated through mammography screening data. Breast Cancer Res (2008) 1.43
Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res (2008) 1.32
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Blood genomics in human stroke. Stroke (2007) 1.05
A bayesian analysis strategy for cross-study translation of gene expression biomarkers. Stat Appl Genet Mol Biol (2009) 1.04
Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res (2004) 0.91
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol (2004) 6.61
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Interaction of YY1 with E2Fs, mediated by RYBP, provides a mechanism for specificity of E2F function. EMBO J (2002) 2.49
Gene expression signatures that predict radiation exposure in mice and humans. PLoS Med (2007) 2.38
Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res (2005) 2.37
Systematic analysis of challenge-driven improvements in molecular prognostic models for breast cancer. Sci Transl Med (2013) 2.34
Linking oncogenic pathways with therapeutic opportunities. Nat Rev Cancer (2006) 2.32
Gene expression phenotypes of atherosclerosis. Arterioscler Thromb Vasc Biol (2004) 2.23
A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell (2009) 2.22
Signaling networks that link cell proliferation and cell fate. J Biol Chem (2002) 1.91
Specificity in the activation and control of transcription factor E2F-dependent apoptosis. Proc Natl Acad Sci U S A (2003) 1.89
MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. Radiology (2013) 1.77
Identification of E-box factor TFE3 as a functional partner for the E2F3 transcription factor. Mol Cell Biol (2003) 1.76
Embracing the complexity of genomic data for personalized medicine. Genome Res (2006) 1.75
Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy. Clin Cancer Res (2006) 1.72
Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription. J Biol Chem (2001) 1.70
Retracted A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2008) 1.69
Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig (2004) 1.68
Genomic prediction of locoregional recurrence after mastectomy in breast cancer. J Clin Oncol (2006) 1.57
Analysis of Cdc6 function in the assembly of mammalian prereplication complexes. Proc Natl Acad Sci U S A (2002) 1.51
The regulated association of Cdt1 with minichromosome maintenance proteins and Cdc6 in mammalian cells. J Biol Chem (2003) 1.46
Novel tumor sampling strategies to enable microarray gene expression signatures in breast cancer: a study to determine feasibility and reproducibility in the context of clinical care. Breast Cancer Res Treat (2009) 1.46
Retracted An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS One (2008) 1.45
Gene expression signatures of radiation response are specific, durable and accurate in mice and humans. PLoS One (2008) 1.44
Age-specific differences in oncogenic pathway deregulation seen in human breast tumors. PLoS One (2008) 1.43
A role for E2F6 in distinguishing G1/S- and G2/M-specific transcription. Genes Dev (2004) 1.42
Balancing the decision of cell proliferation and cell fate. Cell Cycle (2009) 1.36
Combinatorial gene control involving E2F and E Box family members. EMBO J (2004) 1.35
Distinctions in the specificity of E2F function revealed by gene expression signatures. Proc Natl Acad Sci U S A (2005) 1.34
Origin of bistability underlying mammalian cell cycle entry. Mol Syst Biol (2011) 1.32
Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol (2004) 1.29
Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential. Proc Natl Acad Sci U S A (2009) 1.26
Genomic and molecular profiling predicts response to temozolomide in melanoma. Clin Cancer Res (2009) 1.26
Distinct gene expression phenotypes of cells lacking Rb and Rb family members. Cancer Res (2003) 1.26
Network calisthenics: control of E2F dynamics in cell cycle entry. Cell Cycle (2011) 1.25
Using a stem cell-based signature to guide therapeutic selection in cancer. Cancer Res (2010) 1.24
Intratumor heterogeneity and precision of microarray-based predictors of breast cancer biology and clinical outcome. J Clin Oncol (2010) 1.20
An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer. Breast Cancer Res (2009) 1.19
Utilization of pathway signatures to reveal distinct types of B lymphoma in the Emicro-myc model and human diffuse large B-cell lymphoma. Cancer Res (2008) 1.19
Jab1 is a specificity factor for E2F1-induced apoptosis. Genes Dev (2006) 1.17
An integrative approach to characterize disease-specific pathways and their coordination: a case study in cancer. BMC Genomics (2008) 1.14
Genomic strategies for personalized cancer therapy. Hum Mol Genet (2007) 1.14
Retracted Gene-expression patterns predict phenotypes of immune-mediated thrombosis. Blood (2005) 1.12
Utilization of genomic signatures to identify phenotype-specific drugs. PLoS One (2009) 1.12
Molecular evidence for arterial repair in atherosclerosis. Proc Natl Acad Sci U S A (2005) 1.09
Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. Proc Natl Acad Sci U S A (2009) 1.09
Diagnosis of partial body radiation exposure in mice using peripheral blood gene expression profiles. PLoS One (2010) 1.07
Optimizing aptamer activity for gene therapy applications using expression cassette SELEX. Mol Ther (2002) 1.06
Gene expression profiling for prediction of clinical characteristics of breast cancer. Recent Prog Horm Res (2003) 1.04
Stochastic E2F activation and reconciliation of phenomenological cell-cycle models. PLoS Biol (2010) 1.03
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
Temporal control of cell cycle gene expression mediated by E2F transcription factors. Cell Cycle (2005) 1.03
Patterns of cell signaling pathway activation that characterize mammary development. Development (2008) 1.02
Bayesian analysis of binary prediction tree models for retrospectively sampled outcomes. Biostatistics (2004) 1.02
Myc-induced microRNAs integrate Myc-mediated cell proliferation and cell fate. Cancer Res (2010) 1.01
Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia. Proc Natl Acad Sci U S A (2007) 1.01
Phylogenetic simulation of promoter evolution: estimation and modeling of binding site turnover events and assessment of their impact on alignment tools. Genome Biol (2007) 0.99
A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. Clin Cancer Res (2009) 0.98
Utilization of genomic signatures to direct use of primary chemotherapy. Curr Opin Genet Dev (2008) 0.96
Gene expression phenotypes of oncogenic signaling pathways. Cell Cycle (2003) 0.95
Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med (2011) 0.94
SIGNATURE: a workbench for gene expression signature analysis. BMC Bioinformatics (2011) 0.94
Interaction of E2F7 transcription factor with E2F1 and C-terminal-binding protein (CtBP) provides a mechanism for E2F7-dependent transcription repression. J Biol Chem (2013) 0.93
The Rb-related p130 protein controls telomere lengthening through an interaction with a Rad50-interacting protein, RINT-1. Mol Cell (2006) 0.93
Mouse models of cancers: opportunities to address heterogeneity of human cancer and evaluate therapeutic strategies. J Mol Med (Berl) (2010) 0.92
A role for E2F activities in determining the fate of Myc-induced lymphomagenesis. PLoS Genet (2009) 0.90
Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol (2010) 0.90
Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med (2010) 0.87
Retraction: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-80. N Engl J Med (2011) 0.87
FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. Cancer Res (2013) 0.87
Radiogenomics of clear cell renal cell carcinoma: preliminary findings of The Cancer Genome Atlas-Renal Cell Carcinoma (TCGA-RCC) Imaging Research Group. Abdom Imaging (2015) 0.87
Evolving strategies for targeted cancer therapy--past, present, and future. J Natl Cancer Inst (2004) 0.86
Toward the individualization of lung cancer therapy. Cancer (2008) 0.85
Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. Clin Cancer Res (2013) 0.84
A mechanism of COOH-terminal binding protein-mediated repression. Mol Cancer Res (2005) 0.83
Use of gene expression and pathway signatures to characterize the complexity of human melanoma. Am J Pathol (2011) 0.81
A methodology for utilization of predictive genomic signatures in FFPE samples. BMC Med Genomics (2011) 0.80
Retraction for Garman et al: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities. Proc Natl Acad Sci U S A (2011) 0.78
Retraction--Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2011) 0.78